Vaccinating pregnant women against RSV reduced the risk of infection in their infants by 61% compared with newborns with ...

Barré for every million doses given.

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...

The U.S. Food and Drug Administration now requires and has approved safety labeling changes to the prescribing information ...

Pfizer said it will 'support capacity-building initiatives, such as training healthcare professionals and advancing clinical ...

The prescribing information for Abrysvo ® (respiratory syncytial virus [RSV] vaccine) and Arexvy ® (RSV vaccine, adjuvanted) has been updated to include a new warning regarding the risk of ...

Expectant mothers will have access to free vaccines against respiratory syncytial virus (RSV) from next month under a major ...

Most infants born before December were administered nirsevimab, while those whose mothers reached eligible gestational age ...

Nearly 80% of infants born in a California health system were exposed to nirsevimab or the maternal respiratory syncytial ...

“The availability of two different RSV protection methods in sufficient supply may have ... Several authors disclosed ties to pharmaceutical companies, including Pfizer, which manufactures the RSVpreF ...

While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. (NYSE:PFE) Albert Bourla, Chairman and CEO, said, “I ...